Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Onward and upward. I’m ready for another week of action. Best movie in town.
If you want the real story on Leronlimab read the comments at the end of the recent SA write up. That’s where the meat is. That’s where the real truth lies.
As long as the FDA, BP dirty lobbying $, and Dr. Falsi don’t screw CYDY and Leronlimab this is the investment of the year or decade.
Once again skip the write up and go straight to comments.
https://seekingalpha.com/article/4343850-cytodyns-answer-to-covidminus-19
Good synopsis Borel, I would add in the Q&A potion of the webinar Dr. Yang was asked how effective he felt Leronlimab was. Below is his response in his exact words as I recorded and transcribed his answer.
“If I had to guess, so it’s really hard to know because these patients are getting multiple interventions, some of them also getting plasma, some of them are getting HCQ, some are getting IL-6 blockers, but if I had to guess I would say roughly half to two thirds are, look like to me they may be responding, but again a formally controlled clinical study is going to be needed and that is in the works right now.”
Obviously Dr. Yang has to choose his words carefully and not jump to conclusions based on anecdotal information. My take is he believes Leronlimab is the only option especially in late stage Covid-19.
Another tell was he spent less than 20% of his time on Remedsivir, which he said is not the magic bullet and a drug called Selinexor which he is also responsible for conducting a trial. The remaining 80% and the meat of his presentation focused on highlighting Leronlimab and the early results that are very encouraging.
IMO we are in good hands with Dr. Yang running our clinical trials at UCLA. He is articulate and grounded.
There’s a reason behind everything. The S4 will be distorted by shorts tomorrow.
They will make it appear that Nader is jumping ship when in fact he is all in. They will make it appear that he pocketed a boat load of cash when in fact he did not. The tax computation by itself would take a tax professional to compute. Things are not what they seem and the shorts will throw a slick surface story at Nader.
As many loyal Longs understand we are on the cusp of making history and the shorts are going to be relentless because the hole is going to go much deeper. The science is going to move from the back of the room to front and center in the coming weeks.
Hang onto your shares tightly or you will never forgive yourself. The road we are on is disrupting the status quo and will save many lives — and that in its self is a road worth traveling.
AIMHO — GLTA Longs
If Bruce Patterson is correct and I believe he is, Leronlimab is going to disrupt the BP food chain and much more along the way.
The manipulation and fabrication of misinformation is but one example of a desperate and unethical attempt to inhibit the reallocation of Billions of $’s.
Success from a new player is always met with skepticism and resistance whether it be moving from the minor leagues to the majors in baseball or obscurity to disrupting SOC in the biotech world.
CYDY has the goods and the science is gaining traction. The scramble to shed doubt and mount an offensive by the parties that will be displaced is to be expected.
Gilead and Fauchi pulled quite a move on April 16th that exemplifies just that. They changed the metrics and primary end point to get into scoring position first. They reached base on an error not a legitimate base hit.
“Government clinical trial investigators changed the primary metric for measuring the success of Gilead’s experimental drug remdesivir.”
“Instead of counting how many people taking the drug were kept alive on ventilators or died, among other measures, the National Institute of Allergy and Infectious Diseases said it would judge the drug primarily on a different outcome: how long it took surviving patients to recover.”
“The switch — which specialists said is unusual in major clinical trials but not unheard of — was publicly disclosed on the government’s clinicaltrials.gov website on April 16 but did not receive much attention at the time.”
“I think that they thought they weren’t going to win, and they wanted to change it to something they could win on,'' said Steven Nissen, a Cleveland Clinic cardiologist and expert clinical investigator who has led numerous drug trials. “I prefer the original outcome. It’s harder. It’s a more meaningful endpoint.”
“Getting out of the hospital early is useful,'' he said, “but it’s not a game-changer.''
Fauchi and Gilead has set the SOC bar very low. Is it any wonder why Gilead’s CEO, O’Day made the decision to give the drug away at no cost. It has very little value and he knows it.
Leronlimab’s current 75 patient blinded placebo trial results will certainly shine a very bright light on Remdesivir’s shortcomings.
The full story:
https://www.washingtonpost.com/business/2020/05/01/government-researchers-changed-metric-measure-coronavirus-drug-remdesivir-during-clinical-trial/
Oh my, what a predicament. Joining forces with the very company that has wanted to squash Leronlimab like a bug.
I will believe the fomo when Gilead releases a PR verifying such an arrangement. From a business perspective partnering up with Gilead to conduct a CV combo trial cements CYDY’s move off the OTC to Nasdaq. Personally I think we are close to making that move organically without R/S or partnership with BP.
As mentioned our current trials would continue and the truth would be known about Leronlimab’s ability to stand as a single agent treatment for CV. So patients would ultimately not be compromised.
If I’m Gilead why do I want to help the very company that poses the biggest threat to my future? In the short term they have created value with Remdesivir by piggy backing Lenronlimab while adding exposure, credibility, and financial strength for what may be their largest competitor. As I said I’ll believe this move by Gilead when it’s formally announced.
This is quite a chess game. If Nader has a strength it’s his negotiating tenacity. Shaping up to be another interesting day for CYDY.
The clinical data just continues to stack and stack.....TIMBER.
What I like most about Nader is he’s like a Pit Bull with a bone. Good luck getting that bone away from him.
Any long that sells this stock anytime soon is not paying attention. The ride has just begun as uplisting is going be our coming out party.
AIMHO
I am not surprised that Nader and the BOD are taking heat for granting themselves a huge pay day for performing the responsibilities they are already being compensated for. Its like a QB in the fourth quarter of the Super Bowl with his team trailing coming to the sidelines and telling the coach; I think I can take the team down the field and win the game but I think I deserve a big bonus if I get it done. Sorry pal that’s why you get paid the big bucks - do your job and win the game.
As stated by IndexGuy this may be meaningless because BTD may not be granted within the six month window. If it is granted within the window Nader and his boys would be wise to forgo the self awarded shares.
Obviously there is mucho $ circling around this all powerful molecule.
Well, this was exactly what was needed to throw the one two punch at 10am. BLA completed, table is set for this to let the results stack and I’m sure we are going to hear from Patterson and Lalezari just how increasingly positive the data is.
Stick a fork in it.
Makes me proud to have supported a drug that can save lives and family dreams. There is a very big story brewing.
Way to run through the finish line. Talk about a strong close. Pool party this weekend!
Uplisting
No worries. Regardless of the BLA being completed and filed on Monday we are on a very clear path to uplifting to the Nasdaq.
All the pieces are falling into place.
Yes, good one Zuess!
I’ve been here eight years. I can’t remember a CC during trading hours.
Obviously good news. I guess we need a betting line on BLA completion.
Here is the link to the KRON 4 SF Bay Area clip talking about Leronlimab with Lalezari.
https://www.kron4.com/video/coronavirus-drugs-being-studied/5421422/
Just now-flipping through the nightly TV news stations here in the SF Bay Area. Caught the tail end of Lalezari on KRON 4 talking about Leronlimab. Wish I’d seen the entire piece.
Word is getting out.
CYDY
This is wound tight as a spring and ready to explode on positive news.
IMHO the next two catalysts coming any day will be:
- BLA Filed - Yes I’m going ou on a limb.
- Perhaps 30 more patients enrolled for a total of 45 patients for the 75 patient moderate Covid-19 Trial. That would mean full enrollment in a week or two.
I have little doubt the data is going to be strong from this trial replicating what we already know. Leronlimab works on multiple indications and Covid-19 just happens to be one of them.
Consequently CYDY moves from skepticism to validation, from the OTC to the Nasdaq in short order.
Playing w the big boys is within grasp.
AIMHO of course.
Thanks for the clarity BL. You nailed it.
Go low. We still can’t play :(
Way to step out in a limb. I’m saying this week. That’s stepping out on a limb.
Grip,
Can you calm down - this is going up. Maybe not every day but it’s going up. Expect BLA filing this week.
Go break 70 and smell the roses.
Your the only turd here. What a tool.
There are no .25 warrants out there to my knowledge.
The Tender Offer equated to .267 conversion. Company offered .40 conversion plus 1/2 share. That equated to .40 for 1.5 shares.
That offer is long gone.
We are gaining momentum — Just received this in my inbox from Wall Street Reporter.
“We apologize if you were not able to get into last Friday's livestream presentation for CytoDyn.
Our live audience capacity is 1,000 - and we usually get 300-500 investors on our calls.
On Friday almost 2,000 investors from around the world rushed in at the last minute to participate in CytoDyn's update on leronlimab success in treating COVID-19.
(So far, the total number of views for live & video is over 4,500 since Friday!).
We will be increasing investor audience capacity for future
events! “
The Dr. Yang news is getting out. This is the tip of the iceberg. This is going to be one helluva ride.
That’s why the SP is popping.
Just got a text from my Broker.
Dr yang at UCLA is on msnbc now. Talking about Leronlimab.
Says it’s the most promising of the 4 drugs they are working on
Feel like your in my brain BH. Agree with everything you said.
I’m in favor of Patterson and Lalezari doing all of the talking when it comes to the science. Hopefully Nader understands the importance of letting the science guys take the podium.
Personally I’m thrilled to be trading in the mid $2’s. Now an uplist and double digits are within reach.
Here’s to one step closer to monetizing Leronlimab.
Nothing wrong w that strategy. It’s going to get really interesting very soon. Covid-19 is giving Leronlimab the exposure it has needed. I have the utmost confidence the science can endure the clinical testing.
The same people and some newbies sentiment is quite predictable.
When the SP is in a green run they are euphoric. When the SP consolidates they are critical about what isn’t being achieved and talk about running for shelter. That strategy generally ends up costing one dearly.
The ability to see the big picture and the advancement of the clinical data is blurred with “how can the SP be down with so much good news.
Patience and clarity is needed to make the big $ here. It’s going to be a bumpy ride to double digits and beyond. Many here will let their fear talk them out of reality.
I have many seasoned investors that have built in the low $2’s and continue to add every time it runs back to the low $2’s. They see the short’s as another catalyst that will eventually drive the SP up.
The science and clinical data is stacking. As Patterson and Lalezari both stated be patient for a couple of weeks - the world is going to know about Leronlimab.
Happy trading to those that want to make a few $’s. I like many Longs are in it to break the Bank.
For those not able to listen in this call is outstanding. Patterson and Lalazari are knocking it out of the park.
As SH’s Know what you have here. It’s unique and they are making very strong points that make it clear we are the best option for the treatment of Covid-19 at this point in time.
Webinar is full. Well that’s the good news - huge audience that wants the latest. This is a first. Last one had 500 viewers. Wonder what their capacity is?
I guess if you can’t win you’ll have to pretend.
Because he is shorting and has an agenda to discredit leronlimab and CYDY. He’s in this solely for potential financial gain yet he paints the Longs here as greedy money mongers that really don’t care about the Covid-19 victims. He’s a total hypocrite.
Probably close green today.
Took the words right out of my mouth.
“Smart money”.
Your mistake is putting this science in your cookie cutter parameters that say short this turd. You miscalculated.
This turd is going to be your worst nightmare Mr. Big Shot.